ValiRx PLC (VAL)

Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

0.30p

Buy

0.34p

arrow-down-0.045p (-12.33%)

Prices updated at 12 Dec 2025, 16:36 GMT
| Prices minimum 15 mins delay
|
Prices in GBX
ValiRx PLC is a biopharmaceutical company. It is engaged in developing technologies and products in oncology therapeutics and diagnostics focused on the treatment of cancer and associated Biomarkers, specializing in epigenomic and genetic analysis.
FTSE All-Share
arrow-down-0.48%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Martin John Gouldstone
CEO
Dr. Mark Edward Eccleston
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
14
Head office
Chelmsford Road
Hatfield Heath
United Kingdom
CM22 7BD
mobile
+44 1157840025
letter
info@valirx.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Martin John Gouldstone
Non-Executive Director, Chairman
-
Ms. Catherine Jane Tralau-Stewart
Non-Executive Director
-
Mr. Gerald Desler
Executive Director, Chief Financial Officer and Company Secretary
-
Dr. Mark Edward Eccleston
Executive Director, Chief Executive Officer
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
No data

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
21 Nov 2025Purchase
21 Nov 2025Purchase
21 Nov 2025Purchase
21 Nov 2025Purchase
31 Dec 2024Transfer in
31 Dec 2024Purchase
31 Dec 2024Transfer in
31 Dec 2024Purchase
31 Dec 2024Purchase
31 Dec 2024Purchase
31 Dec 2024Transfer in
31 Dec 2024Purchase
31 Dec 2024Transfer in
31 Dec 2024Purchase
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.